Tag: ViiV Healthcare

ViiV Healthcare announces start of the CARISEL study for injectable treatment for HIV

ViiV Healthcare announces superior efficacy cabotegravir for HIV-PrEP

ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment

ViiV HIV prevention trial stopped early on the efficacy

ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and...

U.S FDA issues complete response letter to ViiV Healthcare for the use of investigational cabotegravir and rilpivirine long-acting regimen for the treatment of HIV

ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir DTG 50mg film-coated tablet (FCT) in paediatric HIV...